Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: A single institute experience

Hdl Handle:
http://hdl.handle.net/10147/324633
Title:
Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: A single institute experience
Authors:
Shikhrakab, H; Elamin, YY; O Brien, C; Gately, K; Finn, S; O’Byrne, K; Osman, N
Citation:
Shikhrakab H et al. Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: A single institute experience. IMJ. 2014 107(7)
Publisher:
Irish Medical Journal
Journal:
Irish Medical Journal
Issue Date:
Jul-2014
URI:
http://hdl.handle.net/10147/324633
Abstract:
Epidermal growth factor receptor (EGFR) gene mutations determine the treatment and prognosis in lung adenocarcinoma. Exon 19 and exon 21 (L858R) deletions represent the most common recognised mutations detected. To date, no figures regarding the prevalence of EGFR mutations in the Irish population have been published. The prevalence of EGFR mutations was retrospectively analysed for all patient samples tested since the introduction of EGFR testing routinely (Mar to Dec 2012) in a single Irish institute. The presence of 41 known treatment linked EGFR mutations in exons 18, 19, 20 and 21 of the EGFR gene was tested in 209 Irish patients. Resection, core biopsy or FNA samples were analysed using a commercially available CE-IVD marked multiplex real-time PCR assay. Samples were included from patients of curative and palliative treatment intent likely to harbour an EGFR mutation.
Item Type:
Article
Language:
en
Keywords:
LUNG CANCER; GENETICS

Full metadata record

DC FieldValue Language
dc.contributor.authorShikhrakab, Hen_GB
dc.contributor.authorElamin, YYen_GB
dc.contributor.authorO Brien, Cen_GB
dc.contributor.authorGately, Ken_GB
dc.contributor.authorFinn, Sen_GB
dc.contributor.authorO’Byrne, Ken_GB
dc.contributor.authorOsman, Nen_GB
dc.date.accessioned2014-08-11T13:10:34Z-
dc.date.available2014-08-11T13:10:34Z-
dc.date.issued2014-07-
dc.identifier.citationShikhrakab H et al. Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: A single institute experience. IMJ. 2014 107(7)en_GB
dc.identifier.urihttp://hdl.handle.net/10147/324633-
dc.description.abstractEpidermal growth factor receptor (EGFR) gene mutations determine the treatment and prognosis in lung adenocarcinoma. Exon 19 and exon 21 (L858R) deletions represent the most common recognised mutations detected. To date, no figures regarding the prevalence of EGFR mutations in the Irish population have been published. The prevalence of EGFR mutations was retrospectively analysed for all patient samples tested since the introduction of EGFR testing routinely (Mar to Dec 2012) in a single Irish institute. The presence of 41 known treatment linked EGFR mutations in exons 18, 19, 20 and 21 of the EGFR gene was tested in 209 Irish patients. Resection, core biopsy or FNA samples were analysed using a commercially available CE-IVD marked multiplex real-time PCR assay. Samples were included from patients of curative and palliative treatment intent likely to harbour an EGFR mutation.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journalen_GB
dc.subjectLUNG CANCERen_GB
dc.subjectGENETICSen_GB
dc.titleEpidermal growth factor receptor (EGFR) mutation testing, from bench to practice: A single institute experienceen_GB
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.